Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study.
Wu YL, Lin ZJ, Li CC, Lin X, Shan SK, Guo B, Zheng MH, Li F, Yuan LQ, Li ZH. · 2023
Read Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study. by Wu YL, Lin ZJ, Li CC, Lin X, Shan SK, Guo B, Zheng MH, Li F, Yuan LQ, Li ZH. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9981733.txt.
Introduction
Wu and co-authors trace epigenetic control in metabolic diseases and its clinical promise. Epigenetics shapes gene activity and many metabolic conditions. Listed diseases include diabetes, obesity, and fatty liver disease. Osteoporosis, gout, and thyroid disorders appear as well.
Four main routes anchor the review. They are DNA methylation, histone change, chromatin remodeling, and noncoding RNA. Aging, diet, and exercise interact with these systems. Together they help form a person's traits and disease risk. The authors first sketch the field's history since 1942. Research methods come next, then clinical uses. Those uses include biomarkers, new drugs, and gene editing. The review links basic routes to bedside aims in plain order.
Catalog record
| CREATOR | Wu YL, Lin ZJ, Li CC, Lin X, Shan SK, Guo B, Zheng MH, Li F, Yuan LQ, Li ZH. |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 192 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study By Yan-Lin Wu, Zheng-Jun Lin, Chang-Chun Li, Xiao Lin, Su-Kang Shan, Bei Guo, Ming-Hui Zheng, Fuxingzi Li, Ling-Qing Yuan, Zhi-hong Li Published in: Signal Transduction and Targeted Therapy DOI: 10.1038/s41392-023-01333-7 ABSTRACT Abstract Epigenetics regulates gene expression and has been confirmed to play a critical role in a variety of metabolic diseases, such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), osteoporosis, gout, hyperthyroidism, hypothyroidism and others. The term ‘epigenetics’ was firstly proposed in 1942 and with the development of technologies, the exploration of epigenetics has made great progresses. There are four main epigenetic mechanisms, including DNA methylation, histone modification, chromatin remodelling, and noncoding RNA (ncRNA), which exert different effects on metabolic diseases. Genetic and non-genetic factors, including ageing, diet, and exercise, interact with epigenetics and jointly affect the formation of a phenotype. Understanding epigenetics could be applied to diagnosing and treating metabolic diseases in the clinic, including epigenetic biomarkers, epigenetic drugs, and epigenetic editing. In this review, we introduce the brief history of epigenetics as well as the milestone events since the proposal of the term ‘epigenetics’. Moreover, we summarise the research methods of epigenetics and introduce four main general mechanisms of epigenetic modulation. Furthermore, we summarise epigenetic mechanisms in metabolic diseases and introduce the interaction between epigenetics and genetic or non-genetic factors. Finally, we introduce the clinical trials and applications of epigenetics in metabolic diseases. Subject terms: Epigenetics, Endocrine system and metabolic diseases INTRODUCTION Metabolic diseases are a growing worldwide health challenge due to their dramatically increasing incidence.1,2 These diseases include obesity,3 type 2 diabetes (T2D),4 nonalcoholic fatty liver disease (NAFLD),5 osteoporosis,6 gout,7 hyperthyroidism8 and hypothyroidism.9 Diabetes has become the ninth major cause of death worldwide. According to the statistics of the International Diabetes Federation (IDF),10 537 million adults had diabetes in 2021, of which more than 90% had T2D. The number is estimated to increase to 783 million by 2045. Besides, obesity has become a primary public health problem globally and a dramatically increasing prevalence of overweight and obesity has also been observed during the past decades. More than 1.9 billion adults and over 650 million adults were obese or overweight, respectively, around the world in 2016, which accounted for approximately 39% of the global population.11 The most recent national survey based on the Chinese population showed that 34.3% of adults were overweight and 16.4% of adults were obese.12 With a global prevalence of 25%, NAFLD has become the most common chronic liver disease worldwide.13 It is estimated that in 2019, the global prevalence of NAFLD in Asia was 29.62%.14 In addition, gout is the most common category of inflammatory arthritis caused by the deposition of monosodium urate (MSU) crystals in articular and non-articular structures, with a prevalence of 1–4% and an incidence of 0.1%–0.3% worldwide.15 These data indicate that metabolic diseases are a severe burden in human society owing to the ensuing high morbidity and mortality; hence, uncovering the mechanisms and therapeutics of metabolic diseases is essential. The underlying mechanisms of metabolic diseases are multifaceted, and both genetic and non-genetic factors are critically responsible for the initiation and development of metabolic diseases.1,16 Emerging evidence indicates that epigenetic regulation plays a crucial role in the occurrence and progression of diverse metabolic diseases.16–21 Epigenetics is regarded as various covalent modifications of nucleic acids and histone proteins which regulate gene function and expression and the chromatin structure cooperatively.22–24 Epigenetic regulation can occur at various levels, including through DNA methylation, histone modifications, chromatin remodelling, and noncoding RNA (ncRNA) modulation.24–26 Epigenetics is fundamental to several biological processes, such as cell differentiation, replication, and adhesion.27–29 Notably, multiple epigenetic modifications are significantly correlated with metabolic disease-related gene function and expression and often occur early in diseases, thus exhibiting promising potential as clinical biomarkers for patients with metabolic diseases.30–32 Epigenetic-based diagnostic and therapeutic efficacy prediction and evaluation tools greatly contribute to precision medicine in metabolic diseases.21,33,34 Moreover, epigenetic regulation is reversible and dynamically modulated, meaning that epigenetic-related changes to genes and proteins could serve as novel therapeutic targets in clinical settings.17 Therefore, deciphering the epigenetic regulation of metabolic diseases is crucial to understand metabolic diseases initiation and progression, and to develop novel preventive or curative therapeutic strategies in clinical metabolic disease management. In this review, we introduce the history and four general mechanisms of epigenetic modulation and systematically summarise recent progress regarding the roles of epigenetic regulation in metabolic diseases as well as the underlying mechanisms. Besides, we discuss the clinical applications of epigenetic regulation as promising epigenetic biomarkers and novel therapeutic targets in metabolic disease treatment. OVERVIEW OF EPIGENETICS A brief history of epigenetics In 1942, the English developmental biologist Conrad Hal Waddington proposed the new term ‘epigenetics’ as the processes by which the genotype brings the phenotype into being.35 Moreover, in 1957, Waddington published his famous drawing of the ‘epigenetic landscape’, which suggested that the process of cellular differentiation may be regulated by changes in the ‘epigenetic landscape’ instead of alterations in genetic inheritance.36 DNA modifications were discovered in 1948,37 and in 1975, Holliday et al.38 illustrated that DNA methylation are involved in gene regulation, particularly 5-methylcytosine (5mC). Furthermore, in 1980, Razin et al.39 found that DNA methylation represses gene function and differentiation. In 1964, histone modifications, especially acetylation, were described for the first time, and researchers discovered their close relationship with the regulation of RNA synthesis.40 The currently model of the nucleosomal organisation of chromatin was proposed in 1974.41 The model describes that the basic unit of chromatin is the nucleosome particle, which consists of four histones (histone octamers) and 147 base pairs of DNA wrapped around them. In 1976, Sanger42 first discovered circular RNA (circRNA) molecules in Viroids. H19 was identified as the first long ncRNA (lncRNA) involved in epigenetic regulation in 1990.43 In 1994, the first microRNA (miRNA), lin-4, was discovered in the nematode Caenorhabditis elegans by Lee and colleagues.44 In 1997, the crystallographic structure of the nucleosome core particle of chromatin was visualised by X-ray.45 In 1996, the first nuclear histone acetyltransferase (HAT) and the first histone deacetylase (HDAC) were discovered separately.46,47 Since the beginning of the 21st century, epigenetics has developed rapidly, and there has been a tremendous amount of research published. In 2000, SUV39H1 was discovered as the first histone lysine methyltransferase (KMT), which selectively trimethylates histone H3 lysine 9 (H3K9me3).48 In 2004, the first histone lysine demethylase (KDM), LSD1, was discovered. In 2006, the first wave of epigenetic drugs, including decitabine and vorinostat, was approved by the U.S. Food and Drug Administration (FDA) and was used to treat human cancers. In 2012, oncohistones were first reported as mutations in histone genes, which were related to cancer.49,50 In 2015, the U.S. National Institutes of Health (NIH) Roadmap Epigenomics Consortium published 111 human reference epigenomes.51 In less than 100 years, the concept of epigenetics has developed rapidly. We summarise the milestone events related to epigenetics in Fig. 1. [Figure: The milestone events related to epigenetics. Key discoveries are highlighted] Methods to study epigenomic and epigenetic states There are growing interests in the functions of epigenomics and the related molecular mechanisms. Thus, the development of new technologies contributes to providing a better understanding of epigenomics (Table 1). [Table: